
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the company's tree pollen tablet (ITULAZAX®) and house dust mite tablet (ACARIZAX®) for children with moderate to severe allergic rhinitis whose symptoms are not controlled by symptomatic treatment. ITULAZAX® is recommended for children aged 5 to 17 with birch pollen allergy and ACARIZAX® for children aged 5 to 11 with house dust mite allergy, making both tablets available to eligible children through the National Health Service (NHS).










